

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for the treatment of sinusitis comprising a therapeutically effective amount of a peptide having a C-terminal sequence amino acid sequence KPV in combination with a therapeutically effective amount of a decongestant/antihistamine.
- 5 2. The pharmaceutical composition of claim 1 wherein the peptide is selected from the group of peptides with a C-terminal amino acid sequence consisting of: KPV, VPK-Ac-CC-Ac-KPV, HFRWGKPV and SYSMEHFRWGKPV.
3. The composition of claim 1 wherein said decongestant/antihistamine is selected from the group consisting of: pseudoephedrine, phenylephrine, phenylpropanolamine, chlorpheniramine, bromopheniramine, pheniramine and loratidine.
4. The composition of claim 1 further comprising a therapeutically effective amount of an antibiotic.
5. The composition of claim 4 wherein said antibiotic is selected from the group consisting of: amoxicillin, ampicillin, azithromycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cefpodoxime proxetil, clarithromycin, and azithromycin.
6. The composition of claim 1 further comprising a therapeutically effective amount of a glucocorticosteroid.
7. The composition of claim 6 wherein said glucocorticosteroid is selected from the group
20 consisting of: betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisone, prednisone, triamcinolone.
8. The composition of claim 1 further comprising a therapeutically effective amount of a fungicide.

9. The composition of claim 8 wherein said fungicide is selected from the group consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.
10. The pharmaceutical composition of claim 1 further contained in a carrier.
11. The composition of claim 10 wherein the concentration of said peptide is at least 10^{-12} M.
- 5 12. The composition of claim 11 wherein the carrier is selected from the group consisting of: saline, phosphate buffered saline, gelatin maltodextrin, cellulose, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose and hydroxymethyl cellulose with glycerin.
13. A pharmaceutical composition for the treatment of sinusitis comprising a therapeutically effective amount of a peptide having a C-terminal sequence amino acid sequence KPV in combination with a therapeutically effective amount of a decongestant/antihistamine and a therapeutically effective amount of a fungicide.
14. The pharmaceutical composition of claim 13 wherein the peptide is selected from the group of peptides with a C-terminal amino acid sequence consisting of: KPV, VPK-Ac-CC-Ac-KPV, HFRWGKPV and SYSMEHFRWGKPV.
15. The composition of claim 13 wherein said fungicide is selected from the group consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.
16. The composition of claim 13 further comprising application of a therapeutically effective amount of an antibiotic.
- 20 17. The composition of claim 16 wherein said antibiotic is selected from the group consisting of: amoxicillin, ampicillin, azithramycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cefpodoxime proxetil, clarithromycin, and azithromycin.

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995

18. The composition of claim 13 further comprising a therapeutically effective amount of a glucocorticosteroid.
19. The composition of claim 18 wherein said glucocorticosteroid is selected from the group consisting of: betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisone, prednisone, triamcinolone.
20. The composition of claim 13 wherein said antihistamine/decongestant is selected from the group consisting of: pseudoephedrine, phenylephrine, phenylpropanolamine, chlorpheniramine, bromopheniramine, pheniramine and loratidine.
21. The pharmaceutical composition of claim 10 further solvated in a carrier.
22. The composition of claim 21 wherein the concentration of said peptide is at least 10^{-12} M.
23. The composition of claim 21 wherein the carrier is selected from the group consisting of: saline, phosphate buffered saline, gelatin maltodextrin, cellulose, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose and hydroxymethyl cellulose with glycerin.
24. A method for the treatment of sinusitis comprising application of a pharmaceutical effective amount of a peptide having a C-terminal sequence amino acid sequence KPV.
25. The method of claim 24 wherein the peptide is selected from the group with a C-terminal amino acid sequence consisting of KPV, VPK-Ac-CC-Ac-KPV, HFRWGKPV and SYSMEHFRWGKPV.
26. The method of claim 24 further comprising application of therapeutically effective amount of a fungicide.
27. The method of claim 26 wherein said fungicide is selected consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole.

28. The method of claim 24 further comprising application of a therapeutically effective amount of an antibiotic.
29. The method of claim 28 wherein said antibiotic is selected from the group consisting of: amoxicillin, ampicillin, azithromycin, erythromycin, nafcillin, penicillin, amoxicillin/clavulanate potassium, cefuroxime axetil, cefpodoxime proxetil, clarithromycin, and azithromycin.
30. The method of claim 24 further comprising application of a therapeutically effective amount of a decongestant/antihistamine.
31. The method of claim 28 further said decongestant is selected from the group consisting of: pseudoephedrine, phenylephrine, phenylpropanolamine, chlorpheniramine, bromopheniramine, pheniramine and loratidine.
32. The method of claim 24 further comprising application of a therapeutically effective amount of a glucocorticosteroid.
33. The method of claim 32 wherein said glucocorticosteroid is selected from the group consisting of: betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisone, prednisone, triamcinolone.
34. The method of claim 24 wherein said peptide is systemically or topically applied before, during or after surgery performed to treat sinusitis.